74 results match your criteria: "and Norwegian University of Science and Technology[Affiliation]"
Arthritis Rheumatol
December 2024
Oslo University Hospital and University of Oslo, Oslo, Norway.
Objective: The efficacy of tumor necrosis factor inhibitors for treating chronic low-back pain with Modic changes is uncertain. This study investigated the superiority of infliximab over placebo in patients with Modic type 1 changes.
Methods: In this multicenter, randomized, triple-blind, placebo-controlled trial, patients aged 18 to 65 years with moderate to severe chronic low-back pain and Modic type 1 changes were enrolled from five Norwegian public hospitals between January 2019 and October 2022.
Blood Cancer J
April 2024
Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo, Norway.
Arthritis Care Res (Hoboken)
September 2024
Sørlandet Hospital, Kristiansand, and Norwegian University of Science and Technology, Trondheim, Norway.
Arthroscopy
October 2024
Department of Orthopedic Surgery, Trondheim University Hospital and Norwegian University of Science and Technology (NTNU) Trondheim, Norway.
Purpose: To analyze the results of the subscapular sling procedure developed for anterior shoulder instability in patients with less than 10% anterior glenoid bone loss.
Methods: Patients were treated surgically with the arthroscopic subscapular sling procedure. A semitendinosus graft was used to reconstruct the anterior labrum and to establish a sling suspension around the upper part of the subscapularis tendon.
Concerns have been raised about the possibility of effects from exposure to short wavelength light (SWL), defined here as 380-550 nm, on human health. The spectral sensitivity of the human circadian timing system peaks at around 480 nm, much shorter than the peak sensitivity of daytime vision (i.e.
View Article and Find Full Text PDFFam Community Health
August 2024
Research Institute of Child Development and Education, University of Amsterdam, Amsterdam, the Netherlands (Dr Fukkink and Ms Leistra); Centre of Expertise Urban Education, Amsterdam University of Applied Sciences, Amsterdam, the Netherlands (Dr Fukkink); Centre of Expertise Urban Vitality, Amsterdam University of Applied Sciences, Amsterdam, the Netherlands (Ms Booij); and Norwegian University of Science and Technology, Trondheim, Norway (Dr van Verseveld).
Background And Objectives: Various interventions aim to reduce obesity and promote healthy lifestyles among different cultural groups.
Methods: We have conducted a systematic literature review, following PRISMA guidelines (registered at https://doi.org/10.
BMC Health Serv Res
December 2023
UiT The Artic University of Norway, Tromsø, Norway.
Background: The Norwegian health authorities introduced standardized cancer patient pathways (CPPs) in 2015, aiming to reduce practice variations across hospitals and regions, and improve the continuity, coordination and overall quality of the health care service provided to cancer patients. There has been few studies investigating this change, and that have looked into the organisational and economic benefits of standardized pathways, however the element of care and the patient perspective has been especially neglected. This study explored the care element in cancer patient pathways through an in-depth study of patient experiences.
View Article and Find Full Text PDFDig Dis
December 2023
Department of Gastroenterology, Hospital Universitari i Politècnic La Fe, Valencia, Spain.
Background: Crohn's disease (CD) is characterized by the development of complications over the course of the disease. It is crucial to identify predictive factors of disabling disease, in order to target patients for early intervention. We evaluated risk factors of disabling CD and developed a prognostic model.
View Article and Find Full Text PDFBlood Cancer J
July 2023
Department of Hematology, Odense University Hospital, Odense, Denmark.
Mov Disord
April 2023
Université Paris-Saclay, UVSQ, Inserm, Gustave Roussy, Team "Exposome, Heredity, Cancer and Health", CESP, Villejuif, France.
Arthritis Care Res (Hoboken)
September 2023
Oslo University Hospital and Oslo Metropolitan University, Oslo, Norway.
Objective: Biosimilars represent cost-effective alternatives to reference biologic disease-modifying antirheumatic drugs. Our objective was to compare drug effectiveness and drug persistence in the treatment of rheumatoid arthritis (RA), assessing the etanercept biosimilar SB4 in efficacy and safety compared with reference etanercept in a Phase III, randomized controlled trial. We applied EULAR Points to Consider for Comparative Effectiveness Research in a retrospective database study of etanercept and SB4 in patients treated in clinical practice in Norway.
View Article and Find Full Text PDFNeurology
August 2022
From the Centre for Genetic Epidemiology (S.G., A.A.K.S., M.S.), Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany; Department of Neurology (L. Pihlstrom, M.T.), Oslo University Hospital, Norway; Université Paris-Saclay (C.D., P.E.S., O.M., B.P., A.E.), UVSQ, Univ. Paris-Sud, Inserm, Team "Exposome, heredity, cancer and health," CESP, Villejuif, France; Department for Neurodegenerative Diseases (C.S., K.B., T.G., M.S.), Hertie Institute for Clinical Brain Research, University of Tubingen; German Center for Neurodegenerative Diseases (DZNE) (C.S., L.F.B., T.G.), Tübingen; Institute of Human Genetics (M.R.B., P.L.), Helmholtz Zentrum München, Neuherberg, Germany; Luxembourg Centre for Systems Biomedicine (LCSB) (Z.L., P.M., D.B., R.K.), University of Luxembourg, Esch-sur-Alzette, Luxembourg; Molecular Genetics Section (C.E., D.G.H., C.B., A.B.S.,), Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD; Group of Applied Bioinformatics (F.B., M.H., J.K.), University of Tübingen; High Performance and Cloud Computing Group ZDV (F.B., M.H.), University of Tübingen, Germany; Griffith Institute for Drug Discovery (G.D.M.), Griffith University, Don Young Road, Nathan, Queensland, Australia; Department of Neurology (A.Z.), Medical University of Vienna; Department of Neurology (W.P.), Wilhelminenspital, Austria; Department of Clinical and Movement Neurosciences (M.T.), UCL Queen Square Institute of Neurology, University College London, London, UK; Tanz Centre for Research in Neurodegenerative Diseases (E.R, A.L.), University of Toronto; Edmond J. Safra Program in Parkinson's Disease (A.L.), Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN; Division of Neurology (A.L.), University of Toronto; Krembil Brain Institute (A.L.), Toronto, Ontario, Canada; Centre for Molecular Medicine and Innovative Therapeutics (S.K.), Murdoch University, Murdoch, Australia; Perron Institute for Neurological and Translational Science (S.K.), Nedlands, Western Australia, Australia; Department of Neurology and Neurosurgery (P.T.), University of Tartu; Neurology Clinic, Tartu University Hospital (P.T.), Estonia; Sorbonne Université (SU) Unité Mixte de Recherche (UMR) 1127 (S.L., A.B., J.C.C.), Institut du Cerveau et de la Moelle épinière, ICM; Assistance Publique Hôpitaux de Paris (J.C.C.), Department of Neurology, CIC Neurosciences, Paris, France; Univ. Lille (M.C.C.H., E.M.), Inserm, CHU Lille, UMR-S 1172-JPArc-Centre de Recherche Lille Neurosciences & Cognition, Lille, France; Department of Neurology (A.B.D.), Ludwig Maximilians University of Munich; Department of Neurology (A.B.D.), Max Planck Institute of Psychiatry, Munich, Germany; Department of Neurology and Department of Clinical Genomics (A.B.D.), Mayo Clinic Florida, Jacksonville, FL; Department of Neurology (G.M.H.), Medical School, University of Cyprus, Nicosia, Cyprus; Department of Neurology (G.M.H., E.D.), Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece; Center of Clinical Research (L.S.), Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens; 1st Department of Neurology (L.S, A.M.S.), Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of Molecular Medicine (E.M.V.), University of Pavia; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation (E.M.V.), Pavia; UOC Medical Genetics and Advanced Cell Diagnostics (S.P.), S. Andrea University Hospital; Department of Clinical and Molecular Medicine (S.P.), University of Rome, Italy; Department of Biomedical Sciences-Humanitas University (L.S.); Humanitas Clinical and Research Center (L.S.), IRCCS, Via Manzoni 56, Milan, Italy; Parkinson Institute (A.Z., G.P.), Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano, Italia; Department of Neurology (L.B., C.F.), San Gerardo Hospital, Milan; Center for Neuroscience (L.B., C.F.), University of Milano Bicocca, Monza; Institute for Biomedical Research and Innovation (G.A., M.G.), National Research Council, Mangone, Cosenza; Institute of Neurology (A.Q.), Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy; Department of Neurology (L.F.B., D.K.), Northwestern University Feinberg School of Medicine, Chicago, IL; Metabolic Biochemistry (L.F.B.), Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians University; Munich Cluster for Systems Neurology (SyNergy) (L.F.B.), Munich, Germany; Department of Integrative Physiology and Bio-Nano Medicine (H.M., Y.K.), National Defense Medical College, Saitama; Department of Neurology (N.H., K.N.), Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan; Department of Neurology (S.J.C.), Asan Medical Center, University of Ulsan College of Medicine; Department of Neurology (Y.J.K.), Yonsei University College of Medicine, Seoul, South Korea; Luxembourg Centre for Systems Biomedicine (L. Pavelka), University of Luxembourg, Belval, Luxembourg; Radboud University Medical Centre (B.P.C.v.d.W., B.R.B.), Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands; Department of Neurology (J.A.), St Olav's Hospital and Norwegian University of Science and Technology, Trondheim, Norway; Instituto de Medicina Molecular João Lobo Antunes (L.C.G., J.J.F.), Faculdade de Medicina, Universidade de Lisboa; Department of Neurosciences and Mental Health (L.C.G.), Neurology, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte (CHULN); Laboratory of Clinical Pharmacology and Therapeutics (J.J.F.), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal; Division of Molecular Biology and Human Genetics (S.B.), Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University; Division of Neurology (J.C.), Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Parkinson's disease & Movement Disorders Unit, Neurology Service (E.T.), Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) Barcelona (E.T.), Spain; Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders (M.E.), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Catalonia; Fundació per la Recerca Biomèdica i Social Mútua Terrassa (P.P., M.D.F.); Movement Disorders Unit (P.P., M.D.F.), Department of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain; Department of Clinical Neuroscience (K.W.), Karolinska Institutet; Department of Medical Epidemiology and Biostatistics (K.W., N.L.P.), Karolinska Institutet; Department of Neuroscience, Karolinska Institutet (C.R., A.C.B.), Stockholm; Lund University (A.P., C.H.), Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden; University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust (C.E.C.); Faculty of Medicine, Health and Life Sciences (K.E.M.), Queens University, Belfast, United Kingdom; Department of Neurology (M.J.F.), McKnight Brain Institute, University of Florida, Gainesville, FL; Parkinson Research Clinic (R.K.), Centre Hospitalier de Luxembourg; Transversal Translational Medicine, Luxembourg Institute of Health (LIH) (R.K.), Strassen; and Neurology (R.K.), Centre Hospitalier de Luxembourg, Luxembourg.
Mov Disord
September 2022
Université Paris-Saclay, UVSQ, Univ. Paris-Sud, Inserm, Team "Exposome, Heredity, Cancer, and Health", CESP, Villejuif, France.
Nordisk Alkohol Nark
April 2021
Vestfold Hospital Trust, Tønsberg, Norway; Norwegian University of Science and Technology (NTNU), Trondheim, Norway; and St Olav's University Hospital, Trondheim, Norway.
Background: Nursing home (NH) residents are in most cases in older ages and use prescription drugs. As alcohol interacts with many commonly prescribed drugs, NH residents may be more vulnerable to the effects of alcohol.
Aim: To investigate the experiences of health professionals in Norwegian NHs when it comes to residents' alcohol consumption and use of psychotropic drugs, and the facilitation of such use in the NH.
Acta Anaesthesiol Scand
April 2022
Department of Emergency Care and Services, Helsinki University Hospital and University of Helsinki, Finland.
Neurotrauma Rep
December 2021
Department of Psychology, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
Some people experience persistent post-concussion symptoms (PPCS) after mild traumatic brain injury (mTBI). A meaningful clinical classification and scientific progress are hampered by a lack of consensus regarding the phenomenology, assessment, and operationalization of PPCS. Here we demonstrate and evaluate how the methodology used to assess and define persistent symptoms after mTBI influences PPCS as a binary outcome.
View Article and Find Full Text PDFMov Disord
April 2022
UVSQ, Univ. Paris-Sud, Inserm, Team "Exposome, Heredity, Cancer and Health," CESP, Université Paris-Saclay, Villejuif, France.
J Parkinsons Dis
April 2022
Université Paris-Saclay, UVSQ, Univ. Paris-Sud, Inserm, Team "Exposome, heredity, cancer and health", CESP, Villejuif, France.
Eur Neuropsychopharmacol
January 2022
Medical University Graz, Department of Psychiatry & Psychotherapeutic Medicine.
Bipolar disorder (BD) might be associated with higher infection rates of coronavirus disease (COVID-19) which in turn could result in worsening the clinical course and outcome. This may be due to a high prevalence of somatic comorbidities and an increased risk of delays in and poorer treatment of somatic disease in patients with severe mental illness in general. Vaccination is the most important public health intervention to tackle the ongoing pandemic.
View Article and Find Full Text PDFArthrosc Tech
July 2021
Department of Orthopedic Surgery, Trondheim University Hospital and Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
There are numerous arthroscopic techniques available to address anterior shoulder instability. Complications are various, and in pursuit of new treatment options, an alternative arthroscopic technique with less potential for complications has been developed. The novel subscapular sling with a semitendinosus graft provides both dynamic and static stability.
View Article and Find Full Text PDFArthritis Rheumatol
August 2021
Harbor-UCLA Medical Center and Lundquist Institute for Biomedical Innovation, Torrance, California.
Objective: To assess epicardial adipose tissue volume (EATV) and its link to coronary atherosclerosis and plaque morphology in patients with rheumatoid arthritis (RA) and in age- and sex-matched controls.
Methods: Computed tomography angiography was used to evaluate EATV and coronary plaque in 139 RA patients and 139 non-RA controls. All models assessing the effect of EATV on plaque were adjusted for age, sex, hypertension, diabetes, dyslipidemia, smoking status, family history of coronary artery disease, and obesity (body mass index of ≥30 kg/m ).
Arthritis Care Res (Hoboken)
January 2021
Norwegian University of Science and Technology and St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway.
Objective: Psoriatic arthritis (PsA) can have a significant impact on health-related quality of life (HRQoL). Data on the timing of changes in the HRQoL of patients with PsA are limited. The present study was undertaken to explore associations between sleep disturbance, fatigue, pain, anxiety, depression, general health status, and satisfaction with life before and after a diagnosis of PsA compared to the general population.
View Article and Find Full Text PDFThe perception of time plays a fundamental role in the organisation of basic psychological processes, and as such may also influence migrants' psychological wellbeing. This paper investigates the relationship between the perception of time and immigrants' psychological adaptation (i.e.
View Article and Find Full Text PDFBMC Health Serv Res
May 2020
Department of Circulation and Medical Imaging, Norwegian University of Science and Technology (NTNU), Postbox 8905, 7491, Trondheim, Norway.
An amendment to this paper has been published and can be accessed via the original article.
View Article and Find Full Text PDF